Another outcomes-based contract for Boehringer in USA

Privately-held German pharma major Boehringer Ingelheim and US health insurer Highmark have announced their second value-based contract.

This agreement covers Stiolto Respimat (tiotropium bromide & olodaterol) inhalation spray for the treatment of chronic obstructive pulmonary disease (COPD), and is the first such contract for Highmark that includes Medicare plans in addition to commercial health plans.

Using the Global Initiative for Chronic Obstructive Lung Disease guideline-based care as a benchmark, Highmark will evaluate whether Stiolto Respimat reduces the total cost for both in-patient and out-patient COPD care for members, compared to the costs for members who use other drugs to treat the health condition.